---
title: 'Vice President, Development Asset Leader, Liver Franchise at Prime Medicine'
canonical: 'https://feeny.ai/job/vice-president-development-asset-leader-liver-franchise-prime-medicine-cambridge-8pm112r9zvhj'
type: 'job'
last_seen: '2026-11-05'
---

# Vice President, Development Asset Leader, Liver Franchise at Prime Medicine

- **Company:** Prime Medicine
- **Location:** Cambridge, MA
- **Compensation:** $360k–$408k
- **Posted:** 2026-10-29
- **Last confirmed live:** 2026-11-05
- **Apply:** https://job-boards.greenhouse.io/primemedicine/jobs/6238887004

## Job description

Company Overview:

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. For more information, please visit [www.primemedicine.com](http://www.primemedicine.com/).

Prime Medicine is a clinical-stage biotechnology company pioneering Prime Editing, a novel and precise "search-and-replace" gene editing technology capable of correcting the vast majority of disease-causing genetic mutations. Our approach allows us to make virtually any type of genetic edit — insertions, deletions, and all base-to-base conversions — without introducing double-strand breaks or requiring a separate donor DNA template. We are advancing a broad pipeline of Prime Editing–based therapies, including in vivo liver-directed programs and ex vivo approaches for ultra-rare disease, with a mission to develop one-time, curative genetic therapies for patients with limited or no treatment options today.

Position Overview

Location: Cambridge, MA (hybrid — min. 3-days a week onsite)

Reports to: VP, Programs and Strategy

Level: VP

Prime Medicine is seeking an experienced, strategic, and operationally rigorous Development Asset Leader to assume leadership of our in vivo LNP-delivered liver programs as they advance from early clinical development through licensure, beginning with our Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs.

The Asset Leader will step in seamlessly once a liver program has cleared IND and owns the asset through clinical PoC and regulatory approval/licensure. As Prime's liver portfolio grows, this leader is expected to scale from single-asset ownership into a franchise-level leadership capability, building the processes, governance, and team structure to efficiently deploy our capital to advance multiple concurrent clinical assets.

The ideal candidate is equally comfortable engaging with both internal (executive management and Board) and external (regulatory authorities, KOLs, CRO/CDMO leadership) stakeholders as they are running a cohesive cross-functional team, building genuine esprit de corps across a lean organization while holding the asset accountable to timeline, budget, and scientific rigor.

Primary Responsibilities

- Own the Integrated Development Plan for liver assets from IND acceptance through regulatory approval/licensure, including trial design input, data package strategy, and key go/no-go decision points
- Anticipate, frame, and escalate the critical considerations that materially change the asset's risk/value profile to executive management
- Lead a matrixed team spanning Clinical, Regulatory, CMC/Manufacturing, Biostatistics, Pharmacovigilance, Med Affairs/Patient Advocacy, and Commercial
- Deploy, where appropriate, AI-enabled project management tooling (timelines, risk registers, cross-functional dashboarding)
- As the liver franchise expands, help design the team structure, governance cadence, and knowledge-transfer processes to advance Prime’s portfolio
- Serve as a key point of contact with CROs/CDMOs, KOLs, and patient advocacy groups for the asset, and represent the asset in regulatory interactions alongside Regulatory Affairs

## Preferred Qualifications

- Advanced degree in life sciences, medicine, or related field (PhD, MD, PharmD) preferred; equivalent industry experience considered
- 12+ years of drug development experience in biotech/pharma, with demonstrated leadership of a clinical-stage asset from IND through late-stage development
- Direct experience in genetic medicines (gene/gene editing therapies, RNA-based therapeutics) or rare disease preferred; liver-directed or LNP delivery experience a strong plus
- Track record of cross-functional program leadership and accountability spanning Clinical, Regulatory, CMC, and Nonclinical
- Demonstrated ability to influence without formal authority, build team culture, and manage external partners (consultants, CROs, KOLs) as an extension of the internal team
- Experience or genuine interest in applying AI tools to project/portfolio management
- Comfort operating in a lean, resource-constrained organization where the Asset Leader is expected to build capability

The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus) and an annual long-term incentive award (e.g., equity).

Prime Medicine offers a comprehensive Total Rewards package with robust health, financial, and wellness benefits—including medical, dental, vision, life insurance, a 401(k) match, and equity programs—along with generous paid time off, wellness days, and company-wide recharge breaks.

Our commitment to employee well-being reflects our belief that when we care for our people, we strengthen our ability to put patients first and make meaningful impact together.

U.S. Pay Range $360,000—$408,000 USD

Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.

## About Prime Medicine

## Company Overview
- **One-liner**: Prime Medicine is a biotechnology company using prime editing, a next-generation gene editing technology, to “search and replace” disease-causing genetic mutations and restore normal gene function.
- **Entity Type**: Public (NASDAQ: PRME, IPO October 2022)
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2019
- **Founders**: David Liu, PhD (Scientific Founder); Andrew Anzalone, MD, PhD (Co-founder)

## Core Business
- **Primary industry**: Biotechnology / Gene Editing Therapeutics
- **Target customers**: Patients with genetic diseases; partners include pharmaceutical companies (e.g., Bristol Myers Squibb) and foundations (e.g., Cystic Fibrosis Foundation)
- **Mission**: “To bring the promise of gene editing to patients” and ultimately “cure, halt, and prevent genetic diseases, providing lifelong benefit to patients.”

## Products & Services
- **Prime Editing Platform**: A proprietary gene editing technology that acts like a “DNA word processor” to precisely replace faulty DNA sequences without causing double-strand breaks. Designed to address ~90% of known disease-causing mutations.
- **PM359** (Phase 1/2): Ex vivo prime editing therapy for p47phox Chronic Granulomatous Disease (CGD). Received FDA RMAT designation and orphan drug designation.
- **PM577a** (Phase 1/2): In vivo prime editing therapy for H1069Q-mutated Wilson Disease. Clinical trial application cleared in New Zealand.
- **Alpha-1 Antitrypsin Deficiency (AATD)**: Discovery-stage liver program using LNP delivery.
- **Cystic Fibrosis**: Discovery program supported by Cystic Fibrosis Foundation (up to $15M), using PASSIGE™ technology.
- **Ex vivo CAR-T** (collaboration with Bristol Myers Squibb): Strategic license and broad collaboration to develop and commercialize ex vivo T-cell prime editor products.

## Market Standing
- **Valuation/Market Cap**: $777.8 million (as of mid-2026, per LinkedIn data)
- **Key Metric**: Annual revenue $4.6 million; total funding raised ~$1.02 billion (including post-IPO equity)
- **Notable Investors/Partners**: ARCH Venture Partners, F-Prime, Bristol-Myers Squibb (corporate round $55M in 2024), Google Ventures (post-IPO equity $5M in 2025), Cystic Fibrosis Foundation
- **Growth Signals**: 
  - Clinical data for PM359 published in *The New England Journal of Medicine*; RMAT designation from FDA.
  - Headcount of 154 (down 29.4% YoY, likely reflecting strategic refocusing).
  - Active job postings: 7 (as of mid-2026), with recent uptick in quarterly postings (+40%).

## Competitive Advantages
- **Prime Editing differentiation**: Unlike CRISPR, prime editing does not require double-strand DNA breaks, enabling more precise and predictable edits with fewer unwanted modifications.
- **Broad applicability**: Can theoretically correct ~90% of known disease-causing mutations across many organs and cell types.
- **Strong IP and scientific foundation**: Co-invented by David Liu (Broad Institute), a pioneer in gene editing.

## Strategic Focus
- **Advancing lead programs** (PM359 for CGD, PM577a for Wilson Disease) through clinical development and regulatory approvals.
- **Expanding pipeline** in liver, lung, hematology/immunology/oncology via internal research and strategic partnerships (e.g., BMS for CAR-T).
- **Leveraging delivery technologies** (LNP, AAV, ex vivo electroporation) to enable both in vivo and ex vivo applications.

## Why Work Here
- **Mission-driven culture**: Opportunity to shape the future of gene editing and directly impact patients with genetic diseases.
- **Collaborative environment**: Emphasis on diversity of viewpoints, scientific curiosity, and passion for patient outcomes.
- **Location**: Headquarters in Cambridge, MA – a hub for biotech innovation. Presence also in India.
- **Career development**: Roles span research, clinical, technical development, finance, HR, and informatics. Recent job postings include AI & Informatics Engineer, Senior Scientist, and Director of People & Culture.
- **Perks & culture**: Not explicitly detailed, but the company values “dedicated, scientifically curious individuals” and offers the chance to work with a world-class scientific team.

## Sources
1. [primemedicine.com](https://primemedicine.com/)
2. [primemedicine.com/about/](https://primemedicine.com/about/)
3. [primemedicine.com/careers/](https://primemedicine.com/careers/)
4. [primemedicine.com/pipeline/](https://primemedicine.com/pipeline/)
5. [linkedin.com/company/prime-medicine](https://www.linkedin.com/company/prime-medicine)

## Other roles at Prime Medicine

- [Executive Director, Supply Chain & External Manufacturing](https://feeny.ai/job/executive-director-supply-chain-external-manufacturing-prime-medicine-cambridge-d1vtwfvkgbxn) — Cambridge, MA
- [Director, Program Management](https://feeny.ai/job/director-program-management-prime-medicine-cambridge-dxzc8t3twr7r) — Cambridge, MA
- [Senior Manager, Regulatory Operations](https://feeny.ai/job/senior-manager-regulatory-operations-prime-medicine-cambridge-ykf9exd6d3js) — Cambridge, MA
- [Associate Scientist/Engineer II Technology, Development and Operations - Chemistry](https://feeny.ai/job/associate-scientist-engineer-ii-technology-development-and-operations-chemistry-berd8hcaxt4f) — Cambridge, MA
- [Research Associate, Automation & Assays](https://feeny.ai/job/research-associate-automation-assays-prime-medicine-cambridge-b5v0g65ps2xt) — Cambridge, MA
- [VP, Regulatory Affairs](https://feeny.ai/job/vp-regulatory-affairs-prime-medicine-cambridge-82w65j0854bh) — Cambridge, MA
- [Laboratory Operations Specialist](https://feeny.ai/job/laboratory-operations-specialist-prime-medicine-cambridge-ma2ywgv2pevd) — Cambridge, MA
- [Senior Medical Director, Clinical Development](https://feeny.ai/job/senior-medical-director-clinical-development-prime-medicine-cambridge-mez51gt08bys) — Cambridge, MA
- [Senior Software Quality Specialist](https://feeny.ai/job/senior-software-quality-specialist-prime-medicine-cambridge-yearqxvgjzt1) — Cambridge, MA
- [Senior Scientist / Senior Engineer, LNP Process Development](https://feeny.ai/job/senior-scientist-senior-engineer-lnp-process-development-prime-medicine-h2ma4d77ffav) — Cambridge, MA